Oral Glucocorticoids Linked to Increased Candidemia Risk

June 8, 2026 Dr. Michael Lee – Health Editor Health

Oral glucocorticoids—widely prescribed for autoimmune disorders, asthma, and inflammatory conditions—may elevate the risk of Candidemia, a life-threatening fungal bloodstream infection, by as much as 40% in high-exposure populations, according to a landmark study published in Clinical Infectious Diseases this month. The findings underscore a critical clinical gap: while these steroids remain a cornerstone of therapy, their off-label use in immunocompromised patients demands rigorous fungal surveillance protocols.

  • Key Clinical Takeaways:
    • Oral glucocorticoids increase Candidemia risk by up to 40% in patients with prolonged therapy (>14 days), per a retrospective cohort analysis of 12,456 hospital admissions.
    • Candida auris, a multidrug-resistant strain, accounted for 18% of cases in the study—higher than prior surveillance data suggested.
    • Prophylactic antifungal stewardship programs reduced infection rates by 32% in intervention groups, according to the study’s secondary analysis.

Why Are Glucocorticoids Linked to a Surge in Fungal Infections?

The mechanism is rooted in immunosuppressive pathogenesis. Glucocorticoids suppress Th17 cell activity—the immune system’s first line of defense against Candida species—while simultaneously altering gut microbiota composition, creating a permissive environment for fungal overgrowth. The study’s lead investigator, Dr. Elena Martinez, PhD, a fungal immunologist at Johns Hopkins University, notes that even moderate doses (equivalent to prednisone ≥20mg/day) disrupt mucosal barriers, allowing transluminal migration of Candida into the bloodstream.

From Instagram — related to Clinical Infectious Diseases, Elena Martinez

“We’re seeing a silent epidemic here. Clinicians often attribute Candida infections to indwelling catheters or broad-spectrum antibiotics, but the glucocorticoid signal was consistently the strongest predictor in our multivariate model.”

—Dr. Elena Martinez, PhD

The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and published in Clinical Infectious Diseases (June 2026), analyzed data from 12,456 hospital admissions across 17 U.S. medical centers. Patients on oral glucocorticoids for ≥14 days exhibited a 3.8-fold higher odds ratio for Candidemia compared to matched controls. Notably, Candida auris emerged as a dominant pathogen in 18% of cases—double the prevalence reported in CDC’s 2023 Antibiotic Resistance Threats Report.

How Should Clinicians Adjust Practice in Light of These Findings?

The study’s authors advocate for a risk-stratified approach to glucocorticoid prescribing, particularly in high-risk groups: solid-organ transplant recipients, patients with HIV/AIDS, and those undergoing chemotherapy. Key interventions include:

  • Prophylactic antifungal stewardship: Initiating fluconazole or echinocandin prophylaxis in patients on ≥20mg prednisone daily for >14 days reduced Candidemia incidence by 32% in the study’s intervention arm.
  • Enhanced surveillance: Weekly oral swabs for Candida colonization in high-risk patients, with escalation to blood cultures if symptoms arise.
  • Dose optimization: Tapering regimens to <10mg/day where clinically feasible, with close monitoring for adrenal insufficiency.

For patients already on long-term glucocorticoids, the study highlights the need for board-certified infectious disease specialists to co-manage care. “This isn’t about abandoning glucocorticoids—it’s about integrating fungal risk mitigation into the treatment plan,” says Dr. Raj Patel, MD, a critical care physician at Massachusetts General Hospital and co-author of the study.

“We’ve known for years that steroids suppress immunity, but the magnitude of Candida risk was underappreciated. Now, we can act on it.”

—Dr. Raj Patel, MD

What Happens Next? The Regulatory and Clinical Landscape

The findings align with recent EMA guidance on antifungal stewardship, which now recommends Candida risk assessment for all patients on immunosuppressive therapy. In the U.S., the CDC’s National Healthcare Safety Network (NHSN) is updating its Candidemia reporting criteria to include glucocorticoid exposure as a mandatory data field.

For healthcare systems, the implications are operational. Hospitals may need to revise infection control protocols to include glucocorticoid dosing as a trigger for antifungal prophylaxis. Meanwhile, pharmaceutical companies developing next-generation steroids are under pressure to design compounds with reduced fungal liability profiles.

Looking ahead, the study’s authors are launching a Phase II trial to test whether adjunctive probiotics (e.g., Saccharomyces boulardii) can mitigate Candida overgrowth in steroid-treated patients. Early data from a pilot study at University of Pittsburgh Medical Center suggests a 28% reduction in colonization rates—a finding that could redefine preemptive care strategies.

The bottom line? Glucocorticoids remain indispensable, but their use must evolve. Clinicians now have the evidence to act—proactively screening, monitoring, and intervening before Candidemia becomes a crisis.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.